These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 2166145

  • 1. Small cell bronchogenic carcinoma: a cyclical alternating combination of epirubicin plus cisplatin and cyclophosphamide plus etoposide.
    Casadio M, Lelli G, Giordani S, Boltri B, Blotta A, Busutti L, Ramini R, Falcone F, Pannuti F.
    J Chemother; 1990 Jun; 2(3):199-202. PubMed ID: 2166145
    [Abstract] [Full Text] [Related]

  • 2. Phase II studies on weekly cisplatinum plus epirubicin or etoposide in the treatment of advanced non-small cell bronchogenic carcinoma.
    Lelli G, Casadio M, Giuliotti C, Giordani S, Martoni A, Strocchi E, Pannuti F.
    Chemioterapia; 1986 Aug; 5(4):228-31. PubMed ID: 3021346
    [Abstract] [Full Text] [Related]

  • 3. A phase III study on intermittent versus weekly cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma.
    Lelli G, Casadio M, Farris A, Tononi A, Giordani S, Pannuti F.
    J Chemother; 1989 Apr; 1(2):136-9. PubMed ID: 2659747
    [Abstract] [Full Text] [Related]

  • 4. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD, Bukowski RM.
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study.
    Veronesi A, Cartei G, Crivellari D, Magri MD, Della Valentina M, Foladore S, Trovò MG, Nascimben O, Sibau A, Talamini R.
    Eur J Cancer; 1994 Jan; 30A(10):1474-8. PubMed ID: 7833105
    [Abstract] [Full Text] [Related]

  • 11. Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.
    Johnson DH, Wolff SN, Hainsworth JD, Porter LL, Grosh WW, Hande KR, Greco FA.
    J Clin Oncol; 1985 Feb; 3(2):170-5. PubMed ID: 2981981
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S, Norwegian Lung Cancer Study Group.
    J Clin Oncol; 2002 Dec 15; 20(24):4665-72. PubMed ID: 12488411
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phase II feasibility study of high dose epirubicin-based regimens for untreated patients with small-cell lung cancer.
    Macchiarini P, Chella A, Riva A, Mengozzi G, Silvano G, Solfanelli S, Angeletti CA.
    Am J Clin Oncol; 1990 Dec 15; 13(6):495-500. PubMed ID: 2173392
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.